Researchers at the University of Michigan have had initial success in mice using nanodiscs to deliver a customized therapeutic vaccine for the treatment of colon and melanoma cancer tumors.
“We are basically educating the immune system with these nanodiscs so that immune cells can attack cancer cells in a personalized manner,” said James Moon, the John Gideon Searle assistant professor of pharmaceutical sciences and biomedical engineering.
Personalized immunotherapy is a fast-growing field of research in the fight against cancer.
The therapeutic cancer vaccine employs nanodiscs loaded with tumor neoantigens, which are unique mutations found in tumor cells. By generating T-cells that recognize these specific neoantigens, the technology targets cancer mutations and fights to eliminate cancer cells and prevent tumor growth.
Unlike preventive vaccinations, therapeutic cancer vaccines of this type are meant to kill established cancer cells.
“The idea is that these vaccine nanodiscs will trigger the immune system to fight the existing cancer cells in a personalized manner,” Moon said.
The nanodisc technology was tested in mice with established melanoma and colon cancer tumors. After the vaccination, twenty-seven percent of T-cells in the blood of the mice in the study targeted the tumors.
When combined with immune checkpoint inhibitors, an existing technology that amplifies T-cell tumor-fighting responses, the nanodisc technology killed tumors within 10 days of treatment in the majority of the mice. After waiting 70 days, researchers then injected the same mice with the same tumor cells, and the tumors were rejected by the immune system and did not grow.
“This suggests the immune system ‘remembered’ the cancer cells for long-term immunity,” said Rui Kuai, U-M doctoral student in pharmaceutical sciences and lead author of the study.
“The holy grail in cancer immunotherapy is to eradicate tumors and prevent future recurrence without systemic toxicity, and our studies have produced very promising results in mice,” Moon said.
The technology is made of extremely small, synthetic high density lipoproteins measuring roughly 10 nanometers. By comparison, a human hair is 80,000 to 100,000 nanometers wide.
“It’s a powerful vaccine technology that efficiently delivers vaccine components to the right cells in the right tissues. Better delivery translates to better T-cell responses and better efficacy,” said study co-senior author Anna Schwendeman, U-M assistant professor of pharmacy.
The next step is to test the nanodisc technology in a larger group of larger animals, Moon said.
Receive an email update when we add a new PERSONALIZED IMMUNOTHERAPY article.
The Latest on: Personalized immunotherapy
via Google News
The Latest on: Personalized immunotherapy
- Immune Repertoire Sequencing Market to Surpass US$ 185 Million by 2026 | Synthesis And Healthcare Experts Reviewson August 17, 2019 at 8:05 am
and Instruments), By Application (Cancer Immunotherapy, Biomarker Discovery ... research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting ...
- Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapyon August 15, 2019 at 4:49 am
The company’s lead product candidate, GRANITE, is a personalized neoantigen-based immunotherapy in Phase 1 clinical testing. Gritstone’s second product candidate, SLATE, is a shared neoantigen, ...
- Clinical Trial Offering Personalized Immunotherapy for Mesotheliomaon August 14, 2019 at 8:12 am
Patients with mesothelioma are now eligible for a multicancer clinical trial studying the effectiveness of personalized immunotherapy at the University of California, San Diego Medical Center. The ...
- BriaCell Appoints Richard J. Berman to Board of Directorson August 12, 2019 at 2:47 pm
BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for ...
- Gritstone Oncology Reports Second Quarter 2019 Financial Results and Recent Highlightson August 12, 2019 at 7:01 am
The company's lead product candidate, GRANITE-001, is a personalized neoantigen-based immunotherapy in Phase 1 clinical testing. Gritstone's second product candidate, SLATE-001, is a shared neoantigen ...
- New T cell detection method promises personalized immunotherapy for melanomason August 12, 2019 at 6:42 am
An important new study shows that better T cell detection is now possible using revolutionary technology. T cells are a type of lymphocyte, which in turn belongs to the diverse family of immune cells.
- What the explosion of immunotherapy research means for Canadian cancer patientson August 10, 2019 at 12:36 pm
And also it should be said that immunotherapy is not without its own set of toxicities. The difference is that we are embarking on this road to personalized medicine and we are targeting cancer in a ...
- Better Reagent Offers Personalized Cancer Immunotherapieson August 9, 2019 at 10:27 pm
For example, in cancer immunotherapy (a therapeutic approach that engage patients own immune cells) characterization of T cells that recognize cancer cells is crucial for tailoring personalized ...
- Better tools, better cancer immunotherapyon August 9, 2019 at 7:53 am
For example, in cancer immunotherapy (a therapeutic approach that engages patients own immune cells) characterization of T cells that recognize cancer cells is crucial for tailoring personalized ...
via Bing News